MacroGenics’ HER2 breast cancer drug Margenza approved in US
AstraZeneca, breast cancer, cancer, Daiichi Sankyo, MacroGenics, Margenza, Puma, Seagen
0 Comment
Puma
Trump tax reform uncertainty puts biotech M&A on hold
Biotech, M&A, Pfizer, Puma, Tesaro
0 Comment
Tesaro and Puma are potential takeover targets
Victory for Puma as FDA approves breast cancer drug
breast cancer, fda, FDA approvals 2017, Puma, Roche
0 Comment
Neratinib can be used to reduce risk of disease returning.
Puma gains as Roche breast cancer combo disappoints
asco, ASCO17, breast cancer, cancer, Puma, Roche
0 Comment
ASCO serves up shock as Roche’s data disappoints
FDA advisers back Puma breast cancer drug despite safety worries
breast cancer, cancer, Puma, R&D, Roche
0 Comment
But biotech still has several hurdles to clear – including Roche’s rival.
Roche breast cancer trial success could kill Puma’s rival
Biotech, breast cancer, Puma, R&D, Roche
0 Comment
Perjeta trial success sends rival biotech’s share price crashing.